Arnav Moudgil

Title: Arnav Moudgil: Innovator in Transposon Research

Introduction

Arnav Moudgil is a prominent inventor based in St. Louis, MO (US). He has made significant contributions to the field of genetic research, particularly in the area of transposon technology. With a total of 2 patents, Moudgil's work is paving the way for advancements in genetic mapping and cancer treatment.

Latest Patents

Moudgil's latest patents include compositions of self-reporting transposon (SRT) constructs and methods for mapping transposon insertions. This innovative approach allows for the mapping of transposon insertions from thousands of single cells in parallel, while also measuring mRNA abundance from the same cells. Additionally, he has developed methods for improved treatment of cancer, focusing on increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.

Career Highlights

Arnav Moudgil is affiliated with Washington University, where he conducts his research. His work has garnered attention for its potential applications in both genetic research and clinical settings. Moudgil's innovative methods are expected to enhance the understanding of gene interactions and improve cancer treatment outcomes.

Collaborations

Moudgil collaborates with notable colleagues, including Robi David Mitra and Michael Nathaniel Wilkinson. Their combined expertise contributes to the advancement of research in transposon technology and its applications.

Conclusion

Arnav Moudgil's contributions to the field of genetic research are noteworthy, particularly in the areas of transposon mapping and cancer treatment. His innovative patents and collaborations position him as a key figure in advancing scientific knowledge and improving therapeutic strategies.